| Expression pattern: |
DN |
| Associated gene: |
ID4 |
| Associated microRNA: |
miR-338-5p |
| Biological function: |
circBMI1 acts as a tumor suppressor in AML, inhibiting AML cell proliferation, promoting apoptosis, increasing chemotherapeutic drug sensitivity, and suppressing AML progression in vivo. |
| Molecular mechanism: |
circBMI1 inhibits AML progression by binding miR-338-5p and affecting ID4 expression; its activity in AML cells is exosome dependent. |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (inhibits); apoptosis (promotes); drug resistance (inhibits); chemoresistance (inhibits); exosome (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; ROC Analysis; Survival Analysis; Bioinformatics Analysis; Transfection; CCK8; Annexin V/PI Flow Cytometry; In Vivo Animal Model; IHC (Immunohistochemistry); Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Western Blot |
| Clinical significance: |
circBMI1 could distinguish patients with AML from controls and is a possible clinical diagnostic biomarker; high circBMI1 expression was associated with higher platelet counts, but no significant overall survival or leukemia-free survival difference was observed. |
| Description: |
circBMI1 is downregulated in AML BMMCs and functions as a tumor-suppressive circRNA. It inhibits AML cell proliferation and in vivo progression, promotes apoptosis, and increases sensitivity to daunorubicin and homoharringtonine through the miR-338-5p/ID4 axis. The study also indicates that circBMI1 can be carried by exosomes and may serve as a diagnostic biomarker and potential therapeutic tool in AML. |
| Confidence score: |
0.7878 |